Discontinuation rates 8.7-9.7%
The trial, funded by Novo Nordisk, the manufacturer of Wegovy (semaglutide), found the drug improved liver inflammation, scarring (fibrosis), and sometimes both in people with metabolic dysfunction-associated steatohepatitis (MASH)
GLP-1-based treatments mark a major advancement in managing obesity and type 2 diabetes, offering added benefits for heart and brain health
The authors declare no additional competing interests
Normal Plateau A weight loss plateau lasting 46 weeks after months of steady progress is normal and temporary
Because semaglutide is on the FDA shortage list, making it commercially unavailable, compounding pharmacies have legally been allowed to step in to provide the medication compounded with vitamins - like B12 or B6. And yes, Jordan says, this is a very safe option